结合性心力衰竭COVID-19患者的并发症和死亡风险:综合分析
Yi Liu1,2,3, Dengao Li4,2,3, Yuchen Liang5
1College of Electronic Information and Optical Engineering, Taiyuan University of Technology, Taiyuan, 030024, China.
Heliyon
|August 22, 2024
概括
COVID-19对心力衰竭患者产生了重大影响,揭示了死亡风险因素的种族差异. 定制的风险评估和管理对于公平的医疗保健结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 在全球范围内,COVID-19大流行给医疗保健系统带来了重大挑战.
- 患有并发症的患者,如心力衰竭,患病率和死亡率高.
- 了解这些不同种族群体之间的影响是不完整的.
研究的目的:
- 在COVID-19大流行期间调查心力衰竭和并发症的特征.
- 为了确定不同种族群体中临床生物标志物和死亡率因素的变化.
- 突出需要定制风险评估和管理策略的需要.
主要方法:
- 对4711名患者的大队伍的分析,分为充血性心力衰竭 (CHF) 和非CHF组.
- 生物标记分析 (血液尿素,阿斯巴酸氨基转移酶,白细胞计数).
- 统变逻辑回归,统变考克斯回归,以及按种族分层的卡普兰-梅尔分析.
主要成果:
- 根据CHF状态观察到生物标志物的显著变化.
- 种族分层显示了多个变量中的显著差异,包括CHF患病率.
- 年龄和并发症是突出的死亡率因素,种族群体之间有不同的模式.
结论:
- 该研究在不同种族群体的COVID-19大流行期间确定了心力衰竭的不同死亡风险因素.
- 调查结果强调了针对不同人群量身定制的风险评估和管理的重要性.
- 结果支持开发有针对性的干预措施,以促进公平的医疗保健结果.
相关概念视频
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405


